Approaching the controversies in antibacterial management of cancer patients.
The principles for management of infectious complications in cancer patients are continuing to evolve. The critical element includes the prompt institution of broad-spectrum antibiotic(s) empirically when granulocytopenic patients become febrile and continuation and modification of the regimen in patients with persistent fever and granulocytopenia. The view is presented that antibiotics provide systemic prophylaxis as well as therapy in persistently granulocytopenic patients and that they should be continued until all signs of infection have cleared or the granulocyte count has recovered. Such aggressive therapy, supplemented by continued evaluation and monitoring of the patient, can significantly reduce infection-relation morbidity and mortality.
D000380:Agranulocytosis / Q000188:drug therapy / Q000276:immunology; D000907:Antibodies, Bacterial; D000917:Antibody Formation; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D002442:Ceftazidime; D002511:Cephalosporins / Q000627:therapeutic use; D002557:Cerebrospinal Fluid Shunts / Q000009:adverse effects; D004357:Drug Synergism; D005335:Fever of Unknown Origin / Q000188:drug therapy; D005547:Foreign Bodies / Q000150:complications; D006801:Humans; D009181:Mycoses / Q000517:prevention & control; D009369:Neoplasms / Q000150:complications*; D010406:Penicillins / Q000627:therapeutic use; D012141:Respiratory Tract Infections / Q000628:therapy; D012306:Risk
D000907:Antibodies, Bacterial; D002511:Cephalosporins; D010406:Penicillins; D002442:Ceftazidime